CNV 2197944

Drug Profile

CNV 2197944

Alternative Names: CNV-2197944

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer Calchan
  • Class Analgesics; Small molecules
  • Mechanism of Action N type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic neuropathies; Postherpetic neuralgia
  • No development reported Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Pain(In volunteers) in United Kingdom (PO)
  • 30 Jun 2014 Convergence Pharmaceuticals completes a phase II trial in Diabetic neuropathies in Hungary, Czech Republic, Bulgaria & Poland (NCT01893125) (EudraCT2013-000407-16)
  • 06 Feb 2014 Convergence Pharmaceuticals completes a phase II trial in Postherpetic neuralgia in Bulgaria and South Africa (NCT reference)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top